Dade Responds to Ortho/MLA Joint Venture
Executive Summary
In July 1994, J&J division Ortho Diagnostic Systems initiated a hematology joint venture with Medical Laboratory Automation to market MLA’s hemostasis instruments with Ortho’s hemostasis reagents, a big blow to Dade (then a subsidiary of Baxter), which for years had a similar arrangement with MLA. Now Dade has responded by signing a hematology partnership with Toa Medical Electronics.
You may also be interested in...
On the Verge of a Deal for Dade Behring
A year ago, Dade Behring, the nation's sixth largest diagnostics company, was facing a huge debt and very angry debt holders. Now, the company seems close to a deal that would allow it to cut the debt in half (to about $750 million) and give debtholders full ownership of Dade Behring. The company would file a voluntary pre-packaged bankruptcy in federal court, which would also enable it to start trading securities on the public equities market. Nothing is finalized, but sources say the company is confident it will prevail. Meanwhile, its financial performance is picking up, with strong growth in all core product lines.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.